Knowledge Sharing

In August 2026, nanobody-based autoimmune therapeutics reached a key milestone.

Alphamab Oncology announced the Phase III results of its HER2 bispecific antibody in first-line breast cancer: Anbenitamab (KN026) in combination with albumin-bound docetaxel met the primary endpoint of progression-free survival (PFS) in study KN026-003, which enrolled patients with HER2-positive advanced breast cancer.

Nanobodies (VHH) are increasingly replacing conventional scFv fragments as CAR extracellular recognition domains, offering a novel strategy for T-cell malignancy therapy.

CLEC12B, as an inhibitory C-type lectin receptor on the surface of NK cells, mediates immune evasion of tumor cells from NK cells, and is a potential target for activating the anti-tumor function of NK cells. Compared with traditional IgG, peptides, and small molecules, targeting CLEC12B nanobodies possess multiple differentiated advantages.

Daiichi Sankyo has launched the Phase I trial of CD25 ADC DS1025a (WO2024204629), recruiting 45 advanced solid tumor patients with interim data due Jan 2028. Built on the mature DXd ADC platform, the agent revitalizes CD25 immunotherapy research. This paper elaborates CD25 biological functions, DS1025a’s mode of action and nanobodies’ superior strengths over traditional full-length mAbs for CD25 drug discovery.

A landmark study recently published in Signal Transduction and Targeted Therapy fully validates the irreplaceable value of nanobodies in cutting-edge innovative immunotherapies. Leveraging nanobody technology, the research team developed the world’s first TCR-mimetic bispecific nanobody-based T-cell engager (TCRm Bi-NbTE). This pioneering platform enables precise targeted therapy against intracellular tumor antigens, filling critical technical gaps left by conventional antibody therapeutics.

On June 12, 2026, XKH001, an anti-IL-25 monoclonal antibody injection, completed the first patient dosing in its Phase II clinical trial for COPD. This milestone signifies a key breakthrough of the IL-25 target in respiratory disease therapy, and also leads the industry to look into the development potential of nanobodies, the cutting-edge next-generation antibody technology.

Published online May 12, 2026, in BMC Biotechnology, an international team led by the Pasteur Institute of Iran has developed two humanized anti-VEGF nanobody variants—MHNb136 and MHNb256—with affinity superior to bevacizumab, providing promising next-generation anti-angiogenic candidates for ocular diseases and cancer.

Recently, a major breakthrough has been announced in the biopharmaceutical industry: SIM0613, an innovative LRRC15-targeted antibody-drug conjugate (ADC) developed by Simcere Zaiming, has been officially approved for clinical trials. With outstanding preclinical data, this drug has secured an ...

BackgroundTreatment of advanced solid tumors remains highly challenging. Conventional chemotherapy and targeted therapies suffer from poor specificity, frequent drug resistance, and severe side effects. Most patients lose the chance for curative surgery and face poor prognosis. Combining preci...

Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder affecting millions worldwide. The F508del-CFTR (cystic fibrosis transmembrane conductance regulator) mutation is the primary pathogenic culprit, present in approximately 90% of CF patients. For decades, repairing the p...

Zai Lab and Boehringer Ingelheim have partnered to develop DLL3-targeted dual therapies for ES-SCLC and NEC. The collaboration combines Obrixtamig and Zai Lab’s DLL3 ADC, spotlighting DLL3 as a key target and nanobody technology’s transformative role in antibody drug development.